MARK N LAMPERT
CIK 1233840 · last filed 2023-11-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.67B
Companies
23
Total Filings
42
Lifetime Open-Market Net
$37.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 2,552,306 | $86.20 | $220.02M | $53.01M | 1 | 2023-11-06 |
| OLMA | Director | 3,913,676 | $9.87 | $38.63M | $0 | 1 | 2023-06-21 |
| XOMAP | Director | 1,989,844 | $25.46 | $50.67M | $4.21M | 1 | 2023-01-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 3,350,950 | $2.65 | $8.88M | $35.70M | 1 | 2022-05-20 |
| CGEM | 10%+ Owner | 2,196,240 | $13.70 | $30.09M | $29.67M | 1 | 2022-04-05 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 4,611,909 | $38.00 | $175.25M | $21.84M | 1 | 2020-11-06 |
| Principia Biopharma Inc. (PRNB) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2020-08-20 |
| CALA | 10%+ Owner | 3,712,340 | $0.00 | $1.1K | -$90.66M | 2 | 2020-05-26 |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 1,804,105 | $90.00 | $162.37M | $31.51M | 1 | 2020-01-21 |
| XOMA | 10%+ Owner | 1,335,192 | $41.79 | $55.80M | $57.47M | 1 | 2019-12-20 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 528,891 | $15.70 | $8.30M | $37.17M | 1 | 2019-09-09 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,510,597 | $0.04 | $291.0K | $21.70M | 2 | 2018-11-30 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 10%+ Owner | 951,300 | $8.37 | $7.96M | -$239.32M | 1 | 2017-12-21 |
| CAPS | 10%+ Owner | 0 | $0.29 | $0 | -$1.06M | 5 | 2017-07-18 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 10%+ Owner | 1,109,258 | — | — | $1.03M | 2 | 2017-06-22 |
| XENE | 10%+ Owner | 1,018,197 | $52.10 | $53.05M | $10.27M | 2 | 2017-06-19 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 13,308,459 | — | — | $0 | 1 | 2016-06-27 |
| CCXI | 10%+ Owner | 2,671,577 | $10.22 | $27.30M | $40.29M | 4 | 2015-11-05 |
| RIGL | 10%+ Owner | 799,615 | $32.85 | $26.27M | $680.4K | 1 | 2013-06-11 |
| LGND | 10%+ Owner | 741,627 | $255.54 | $189.52M | $35.05M | 4 | 2012-11-19 |
| NBIX | 10%+ Owner | 8,847,147 | $159.76 | $1.41B | -$647.3K | 2 | 2011-10-14 |
| Astex Pharmaceuticals, Inc (SUPG) Delisted | 10%+ Owner | 11,270,798 | — | — | -$3.63M | 1 | 2010-04-21 |
| RPRX | 10%+ Owner | 10,308,102 | $54.87 | $565.61M | -$6.35M | 2 | 2009-09-16 |
Recent Filings · Page 3 of 5
42 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-01 | ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Buy (P) | +329,000 | $745.7K | EDGAR |
| 2016-06-27 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-11-05 | CCXI | Mixed | −16,467,462 | -$15.11M | EDGAR |
| 2014-07-03 | CAPS | Other (J) | −3,699,378 | -$1.11M | EDGAR |
| 2013-11-06 | CCXI | Buy (P) | +816,396 | $4.02M | EDGAR |
| 2013-11-01 | CCXI | Buy (P) | +2,017,350 | $10.06M | EDGAR |
| 2013-10-10 | CCXI | Buy (P) | +7,736,124 | $41.32M | EDGAR |
| 2013-06-11 | RIGL | Buy (P) | +196,200 | $680.4K | EDGAR |
| 2012-11-20 | — | Buy (P) | +3,570,000 | $14.28M | |
| 2012-11-19 | LGND | Buy (P) | +99,546 | $1.51M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.